RGD Reference Report - Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Behavioral & Substance Use Disorder Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.

Authors: Tsai, SM  Lin, CY  Wu, SH  Hou, LA  Ma, H  Tsai, LY  Hou, MF 
Citation: Tsai SM, etal., Clin Chim Acta. 2009 Jun 27;404(2):160-5. doi: 10.1016/j.cca.2009.03.038. Epub 2009 Mar 28.
RGD ID: 11353804
Pubmed: PMID:19332043   (View Abstract at PubMed)
DOI: DOI:10.1016/j.cca.2009.03.038   (Journal Full-text)

BACKGROUND: Breast cancer patients initiating TEC (including docetaxel, epirubicin, and cyclophosphamide) treatment were genotyped for CYP3A4, CYP3A5, and ABCB1 to identify variability factors of side effects for docetaxel. METHODS: The planned dose of docetaxel per course was formulated according to each patient's height and weight. Each participant had received TEC treatment for 6 consecutive cycles. The single nucleotide polymorphisms (SNPs) of CYP3A4*4 (352A > G), CYP3A4*5 (653C > G), and CYP3A4*18A (20070T > C) for the CYP3A4 gene, CYP3A5*3A (6986A > G) for the CYP3A5 gene, and -41A > G, -145C > G, 1236C > T, 2677G > T(A), and 3435C > T SNPs for the ABCB1 gene were determined by using the restriction fragment length polymorphism of polymerase chain reaction products and the restriction enzymes. RESULTS: Fifty-nine Taiwanese women (mean age, 46 y; range, 30-64 y) treated for breast cancer with TEC were recruited. We found that patients carrying the CYP3A5*1/*3 genotype demonstrated more side effects of fever, pleural effusion, and febrile neutropenia than those with the CYP3A5*3/*3 genotype (p = 0.075, 0.077, and 0.030, respectively); moreover, patients with the ABCB1 2677G/G genotype also showed more side effects of fever and febrile neutropenia than those with other genotypes (p = 0.024 and 0.027), In regard to ABCB1 3435C>T, patients with ABCB1 3435C/C tended to suffer leucopenia (p = 0.057). CONCLUSIONS: There could be correlations between certain side effects of docetaxel treatment and polymorphisms of these metabolic enzymes. Unfortunately, there is not so much evidence due to the small sample size of this study which restricts the statistical power.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
CYP3A5HumanChemotherapy-Induced Febrile Neutropenia susceptibilityIAGP associated with breast neoplasm;DNA:polymorphism:splice junction:6986A>G (human)RGD 
Cyp3a13MouseChemotherapy-Induced Febrile Neutropenia susceptibilityISOCYP3A5 (Homo sapiens)associated with breast neoplasm;DNA:polymorphism:splice junction:6986A>G (human)RGD 
Cyp3a9RatChemotherapy-Induced Febrile Neutropenia susceptibilityISOCYP3A5 (Homo sapiens)associated with breast neoplasm;DNA:polymorphism:splice junction:6986A>G (human)RGD 
CYP3A5HumanDrug-induced Neutropenia susceptibilityIAGP associated with breast neoplasm;DNA:polymorphism:splice junction:6986A>G (human)RGD 
Cyp3a13MouseDrug-induced Neutropenia susceptibilityISOCYP3A5 (Homo sapiens)associated with breast neoplasm;DNA:polymorphism:splice junction:6986A>G (human)RGD 
Cyp3a9RatDrug-induced Neutropenia susceptibilityISOCYP3A5 (Homo sapiens)associated with breast neoplasm;DNA:polymorphism:splice junction:6986A>G (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Cyp3a9  (cytochrome P450, family 3, subfamily a, polypeptide 9)

Genes (Mus musculus)
Cyp3a13  (cytochrome P450, family 3, subfamily a, polypeptide 13)

Genes (Homo sapiens)
CYP3A5  (cytochrome P450 family 3 subfamily A member 5)


Additional Information